Fibrosis progression rates between chronic hepatitis B and C patients with elevated alanine aminotransferase levels

Akiko Fujiwara, Kohsaku Sakaguchi, Shinichi Fujioka, Yoshiaki Iwasaki, Tomonori Senoh, Mamoru Nishimura, Masako Terao, Yasushi Shiratori

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background: We evaluated the annual rate of fibrosis progression in chronic hepatitis B and C patients with elevated alanine aminotransferase (ALT) levels. Methods: Forty-nine chronic hepatitis B patients and 21 chronic hepatitis C patients, each of whom had undergone two or more liver biopsies at an interval of more than 1 year, were enrolled in this retrospective clinical research protocol. The annual rate of fibrosis progression was calculated by dividing the change in fibrosis stage between the first and second liver biopsies by the interval in years between them. Results: The median interval in chronic hepatitis B and Cwas 3.4 (first and third quartiles, 1.8-4.7) and 3.2 (2.1-6.5) years, respectively. Overall, the mean fibrosis progression rate was 0.21 ± 0.31 (mean ± SD) fibrosis units (FU) per year in 49 patients with chronic hepatitis B, and 0.13 ± 0.18 FU/year in 21 patients with chronic hepatitis C. The ALT level was an independent variable correlating with fibrosis progression. In patients whose median ALT level was 70 IU/l or more, the mean fibrosis progression rate was 0.28 ± 0.32 FU/year in 36 patients with chronic hepatitis B, and 0.22 ± 0.23 FU/year in eight patients with chronic hepatitis C. Conclusion: This paired-biopsy study of untreated chronic hepatitis B or C demonstrated that fibrosis progression occurred largely in patients with continuously elevated ALT levels even over a relatively short period, and that liver fibrosis might progress by one stage within an average of 4-5 years of follow-up in patients with elevated ALT of 70 IU/ l or more.

Original languageEnglish
Pages (from-to)484-491
Number of pages8
JournalJournal of Gastroenterology
Volume43
Issue number6
DOIs
Publication statusPublished - Jun 2008

Fingerprint

Chronic Hepatitis B
Chronic Hepatitis C
Alanine Transaminase
Fibrosis
Biopsy
Liver
Clinical Protocols
Liver Cirrhosis

Keywords

  • Alanine aminotransferase
  • Chronic hepatitis B
  • Chronic hepatitis C
  • Fibrosis progression rate
  • Liver fibrosis

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Fibrosis progression rates between chronic hepatitis B and C patients with elevated alanine aminotransferase levels. / Fujiwara, Akiko; Sakaguchi, Kohsaku; Fujioka, Shinichi; Iwasaki, Yoshiaki; Senoh, Tomonori; Nishimura, Mamoru; Terao, Masako; Shiratori, Yasushi.

In: Journal of Gastroenterology, Vol. 43, No. 6, 06.2008, p. 484-491.

Research output: Contribution to journalArticle

Fujiwara, Akiko ; Sakaguchi, Kohsaku ; Fujioka, Shinichi ; Iwasaki, Yoshiaki ; Senoh, Tomonori ; Nishimura, Mamoru ; Terao, Masako ; Shiratori, Yasushi. / Fibrosis progression rates between chronic hepatitis B and C patients with elevated alanine aminotransferase levels. In: Journal of Gastroenterology. 2008 ; Vol. 43, No. 6. pp. 484-491.
@article{dcf2d89a95114dd1852b6f5414331aba,
title = "Fibrosis progression rates between chronic hepatitis B and C patients with elevated alanine aminotransferase levels",
abstract = "Background: We evaluated the annual rate of fibrosis progression in chronic hepatitis B and C patients with elevated alanine aminotransferase (ALT) levels. Methods: Forty-nine chronic hepatitis B patients and 21 chronic hepatitis C patients, each of whom had undergone two or more liver biopsies at an interval of more than 1 year, were enrolled in this retrospective clinical research protocol. The annual rate of fibrosis progression was calculated by dividing the change in fibrosis stage between the first and second liver biopsies by the interval in years between them. Results: The median interval in chronic hepatitis B and Cwas 3.4 (first and third quartiles, 1.8-4.7) and 3.2 (2.1-6.5) years, respectively. Overall, the mean fibrosis progression rate was 0.21 ± 0.31 (mean ± SD) fibrosis units (FU) per year in 49 patients with chronic hepatitis B, and 0.13 ± 0.18 FU/year in 21 patients with chronic hepatitis C. The ALT level was an independent variable correlating with fibrosis progression. In patients whose median ALT level was 70 IU/l or more, the mean fibrosis progression rate was 0.28 ± 0.32 FU/year in 36 patients with chronic hepatitis B, and 0.22 ± 0.23 FU/year in eight patients with chronic hepatitis C. Conclusion: This paired-biopsy study of untreated chronic hepatitis B or C demonstrated that fibrosis progression occurred largely in patients with continuously elevated ALT levels even over a relatively short period, and that liver fibrosis might progress by one stage within an average of 4-5 years of follow-up in patients with elevated ALT of 70 IU/ l or more.",
keywords = "Alanine aminotransferase, Chronic hepatitis B, Chronic hepatitis C, Fibrosis progression rate, Liver fibrosis",
author = "Akiko Fujiwara and Kohsaku Sakaguchi and Shinichi Fujioka and Yoshiaki Iwasaki and Tomonori Senoh and Mamoru Nishimura and Masako Terao and Yasushi Shiratori",
year = "2008",
month = "6",
doi = "10.1007/s00535-008-2183-8",
language = "English",
volume = "43",
pages = "484--491",
journal = "Journal of Gastroenterology",
issn = "0944-1174",
publisher = "Springer Japan",
number = "6",

}

TY - JOUR

T1 - Fibrosis progression rates between chronic hepatitis B and C patients with elevated alanine aminotransferase levels

AU - Fujiwara, Akiko

AU - Sakaguchi, Kohsaku

AU - Fujioka, Shinichi

AU - Iwasaki, Yoshiaki

AU - Senoh, Tomonori

AU - Nishimura, Mamoru

AU - Terao, Masako

AU - Shiratori, Yasushi

PY - 2008/6

Y1 - 2008/6

N2 - Background: We evaluated the annual rate of fibrosis progression in chronic hepatitis B and C patients with elevated alanine aminotransferase (ALT) levels. Methods: Forty-nine chronic hepatitis B patients and 21 chronic hepatitis C patients, each of whom had undergone two or more liver biopsies at an interval of more than 1 year, were enrolled in this retrospective clinical research protocol. The annual rate of fibrosis progression was calculated by dividing the change in fibrosis stage between the first and second liver biopsies by the interval in years between them. Results: The median interval in chronic hepatitis B and Cwas 3.4 (first and third quartiles, 1.8-4.7) and 3.2 (2.1-6.5) years, respectively. Overall, the mean fibrosis progression rate was 0.21 ± 0.31 (mean ± SD) fibrosis units (FU) per year in 49 patients with chronic hepatitis B, and 0.13 ± 0.18 FU/year in 21 patients with chronic hepatitis C. The ALT level was an independent variable correlating with fibrosis progression. In patients whose median ALT level was 70 IU/l or more, the mean fibrosis progression rate was 0.28 ± 0.32 FU/year in 36 patients with chronic hepatitis B, and 0.22 ± 0.23 FU/year in eight patients with chronic hepatitis C. Conclusion: This paired-biopsy study of untreated chronic hepatitis B or C demonstrated that fibrosis progression occurred largely in patients with continuously elevated ALT levels even over a relatively short period, and that liver fibrosis might progress by one stage within an average of 4-5 years of follow-up in patients with elevated ALT of 70 IU/ l or more.

AB - Background: We evaluated the annual rate of fibrosis progression in chronic hepatitis B and C patients with elevated alanine aminotransferase (ALT) levels. Methods: Forty-nine chronic hepatitis B patients and 21 chronic hepatitis C patients, each of whom had undergone two or more liver biopsies at an interval of more than 1 year, were enrolled in this retrospective clinical research protocol. The annual rate of fibrosis progression was calculated by dividing the change in fibrosis stage between the first and second liver biopsies by the interval in years between them. Results: The median interval in chronic hepatitis B and Cwas 3.4 (first and third quartiles, 1.8-4.7) and 3.2 (2.1-6.5) years, respectively. Overall, the mean fibrosis progression rate was 0.21 ± 0.31 (mean ± SD) fibrosis units (FU) per year in 49 patients with chronic hepatitis B, and 0.13 ± 0.18 FU/year in 21 patients with chronic hepatitis C. The ALT level was an independent variable correlating with fibrosis progression. In patients whose median ALT level was 70 IU/l or more, the mean fibrosis progression rate was 0.28 ± 0.32 FU/year in 36 patients with chronic hepatitis B, and 0.22 ± 0.23 FU/year in eight patients with chronic hepatitis C. Conclusion: This paired-biopsy study of untreated chronic hepatitis B or C demonstrated that fibrosis progression occurred largely in patients with continuously elevated ALT levels even over a relatively short period, and that liver fibrosis might progress by one stage within an average of 4-5 years of follow-up in patients with elevated ALT of 70 IU/ l or more.

KW - Alanine aminotransferase

KW - Chronic hepatitis B

KW - Chronic hepatitis C

KW - Fibrosis progression rate

KW - Liver fibrosis

UR - http://www.scopus.com/inward/record.url?scp=47349132573&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=47349132573&partnerID=8YFLogxK

U2 - 10.1007/s00535-008-2183-8

DO - 10.1007/s00535-008-2183-8

M3 - Article

VL - 43

SP - 484

EP - 491

JO - Journal of Gastroenterology

JF - Journal of Gastroenterology

SN - 0944-1174

IS - 6

ER -